DRUG Stock Overview
A biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Bright Minds Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$41.80 |
| 52 Week High | CA$79.02 |
| 52 Week Low | CA$0.93 |
| Beta | 0.49 |
| 1 Month Change | 13.65% |
| 3 Month Change | 14.74% |
| 1 Year Change | 2,043.59% |
| 3 Year Change | 266.67% |
| 5 Year Change | n/a |
| Change since IPO | 54.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| DRUG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.9% | 0.4% | 1.5% |
| 1Y | 2,043.6% | -2.7% | 22.4% |
Return vs Industry: DRUG exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: DRUG exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| DRUG volatility | |
|---|---|
| DRUG Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DRUG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DRUG's weekly volatility has decreased from 208% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Ian McDonald | brightmindsbio.com |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications.
Bright Minds Biosciences Inc. Fundamentals Summary
| DRUG fundamental statistics | |
|---|---|
| Market cap | US$300.76m |
| Earnings (TTM) | -US$753.66k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-399.1x
P/E RatioIs DRUG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRUG income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.07m |
| Earnings | -CA$1.07m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DRUG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 12:41 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bright Minds Biosciences Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Sepehr Manochehry | Eight Capital |